Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cinclus Pharma Holding AB ( (SE:CINPHA) ) has shared an announcement.
Cinclus Pharma has dosed the first patient in its Phase III HEEALING 1 study, which evaluates linaprazan glurate for treating erosive gastroesophageal reflux disease (GERD). This milestone marks a significant step in the development of linaprazan glurate, a drug designed to offer superior healing and symptom relief compared to existing treatments, addressing a significant unmet medical need in patients with severe GERD.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB is a late-stage clinical pharmaceutical company focused on developing treatments for acid-related diseases and disorders of the upper gastrointestinal tract. Their leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which aims to provide more effective healing and symptom relief for gastroesophageal reflux disease (GERD) than current treatments like proton pump inhibitors.
Average Trading Volume: 66,483
Technical Sentiment Signal: Buy
See more data about CINPHA stock on TipRanks’ Stock Analysis page.